Copyright
©2010 Baishideng Publishing Group Co.
World J Cardiol. Jan 26, 2010; 2(1): 13-18
Published online Jan 26, 2010. doi: 10.4330/wjc.v2.i1.13
Published online Jan 26, 2010. doi: 10.4330/wjc.v2.i1.13
Table 1 Baseline clinical characteristics by eGFR group (n = 2160) (mean ± SD)
eGFR≥90 (n = 624) | eGFR 60-89 (n = 1216) | eGFR 15-59 (n = 320) | P value | |
eGFR mL/min every 1.73 m2 | 106.0 ± 16.6 | 75.5 ± 8.1 | 50.4 ± 7.7 | < 0.0001 |
Age (yr) | 54.2 ± 9.7 | 58.7 ± 10.5 | 67.2 ± 9.6 | < 0.0001 |
Female (%) | 14.6 | 20.3 | 43.4 | < 0.0001 |
Diabetes (%) | 20.4 | 18.3 | 30.0 | 0.009 |
Hypertension (%) | 39.3 | 48.4 | 69.1 | < 0.0001 |
Hyperlipidemia (%) | 50.6 | 51.7 | 55.5 | 0.19 |
Family history of CAD (%) | 42.6 | 40.8 | 32.8 | 0.01 |
Current smoker (%) | 51.9 | 36.9 | 22.5 | < 0.0001 |
Prior MI (%) | 9.5 | 12.2 | 10.9 | 0.28 |
Thrombolytic use during initial 24 h of index MI (%) | 16.5 | 20.2 | 20.3 | 0.09 |
Troponin I divided by ULN (ng/mL) (n = 1186) | 125.0 ± 213.9 | 186.3 ± 443.8 | 231.8 ± 516.6 | 0.01 |
Troponin T divided by ULN (ng/mL) (n = 281) | 46.0 ± 73.4 | 69.6 ± 190.4 | 24.1 ± 28.3 | 0.2 |
Days from index MI to randomization | 10.1 ± 7.4 | 11.2 ± 7.8 | 11.6 ± 7.6 | 0.004 |
BMI (kg/m2) | 28.4 ± 5.1 | 28.6 ± 4.9 | 28.5 ± 5.3 | 0.77 |
Heart rate (beats/min) | 72.1 ± 11.5 | 71.4 ± 11.9 | 72.7 ± 12.7 | 0.13 |
Systolic BP (mmHg) | 119.4 ± 17.4 | 120.7 ± 17.7 | 123.9 ± 19.7 | 0.001 |
Diastolic BP (mmHg) | 72.6 ± 11.1 | 72.3 ± 11.4 | 71.8 ± 11.6 | 0.63 |
Discharge medications (%) | ||||
Aspirin | 97.0 | 95.9 | 92.5 | 0.003 |
Ticlopidine or clopidogrel | 73.6 | 73.2 | 70.2 | 0.33 |
Beta blocker | 88.9 | 87.9 | 85.9 | 0.19 |
ACE Inhibitor | 76.4 | 79.0 | 78.8 | 0.31 |
Lipid lowering agent | 85.4 | 81.7 | 73.4 | < 0.0001 |
IRA-LAD (%) | 32.9 | 36.8 | 38.4 | 0.19 |
IRA-Circ (%) | 18.1 | 13.9 | 15.0 | |
IRA-RCA (%) | 49.0 | 49.3 | 46.6 | |
IRA TIMI Flow Grade 0-1 (%) | 99.8 | 99.5 | 99.4 | 0.41 |
Two or three vessel disease (%) | 15.5 | 17.3 | 21.6 | 0.03 |
Collaterals present (Grade 1 and 2) (%) | 89.2 | 88.5 | 86.7 | 0.29 |
Mitral regurgitation (%) | ||||
Grade 0 | 69.0 | 66.1 | 56.9 | < 0.0001b |
Grade 1 | 27.3 | 28.3 | 30.6 | |
Grade 2 | 2.7 | 4.4 | 7.4 | |
Grade 3 | 1.0 | 1.2 | 5.1 | |
End-diastolic volume (mL) (n = 201) | 137.4 ± 55.1 | 124.1 ± 52.8 | 130.4 ± 85.6 | 0.36 |
End-systolic volume ± mL) (n = 201) | 70.7 ± 32.7 | 64.5 ± 32.2 | 71.7 ± 54.2 | 0.45 |
Ejection fraction (n = 2145) | 48.2 ± 10.0 | 47.9 ± 11.3 | 46.2 ± 12.1 | 0.02 |
Wall motion SD/Chord (n = 1677) | -2.9 ± 0.9 | -2.9 ± 0.9 | -3.0 ± 0.9 | 0.84 |
Systolic sphericity index (n = 1677) | 23.3 ± 6.9 | 22.9 ± 6.6 | 24.7 ± 8.5 | 0.003 |
Diastolic sphericity index (n = 1677) | 30.0 ± 6.7 | 30.6 ± 6.5 | 31.5 ± 7.4 | 0.02 |
- Citation: Jorapur V, Lamas GA, Sadowski ZP, Reynolds HR, Carvalho AC, Buller CE, Rankin JM, Renkin J, Steg PG, White HD, Vozzi C, Balcells E, Ragosta M, Martin CE, Srinivas VS, Wharton III WW, Abramsky S, Mon AC, Kronsberg SS, Hochman JS. Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction. World J Cardiol 2010; 2(1): 13-18
- URL: https://www.wjgnet.com/1949-8462/full/v2/i1/13.htm
- DOI: https://dx.doi.org/10.4330/wjc.v2.i1.13